Literature DB >> 26938953

DYNAMIC CHANGES OF THE ANTERIOR CHAMBER ANGLE PRODUCED BY INTRAVITREAL ANTI-VASCULAR GROWTH FACTOR INJECTIONS.

Joanne C Wen1, Scott W Cousins, Stefanie G Schuman, R Rand Allingham.   

Abstract

PURPOSE: To use anterior segment optical coherence tomography (AS-OCT) to evaluate the anterior chamber after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
METHODS: Preinjection and immediate postinjection AS-OCT images were taken and measurements were compared including angle opening distance (AOD) and trabeculo-iris space area (TISA) at 500 μm and 750 μm from the scleral spur (AOD500, AOD750, TISA500 and TISA750, respectively), and the scleral spur angle.
RESULTS: Twenty-one eyes from 21 patients were studied. There was significant narrowing of the temporal AOD500, AOD750, and temporal angle after injection (P = 0.03, 0.01, and 0.02, respectively). The percentage of narrowing of the nasal TISA500 and TISA750 was significantly greater in phakic versus pseudophakic eyes (P = 0.03 and 0.02, respectively). A higher postinjection IOP was correlated with increased narrowing of the nasal AOD500, TISA500, TISA750, and nasal angle (R = 0.22, 0.28, 0.34 and 0.20; P = 0.03, 0.01, 0.005 and 0.04, respectively) and a smaller preinjection anterior chamber depth in phakic eyes (R = 0.53, P = 0.01).
CONCLUSION: After an anti-vascular endothelial growth factor injection, there is significant narrowing of the temporal anterior chamber angle in all eyes and increased narrowing of the nasal angle in phakic compared with pseudophakic eyes. Physicians performing intravitreal injections should be aware of these associations as they may contribute to our understanding of prolonged elevation of IOP after injections.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26938953     DOI: 10.1097/IAE.0000000000001018

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

1.  Prophylaxis with intraocular pressure lowering medication and glaucomatous progression in patients receiving intravitreal anti-VEGF therapy.

Authors:  Jeanette Du; James T Patrie; Xiao-Yu Cai; Bruce E Prum; Yevgeniy Shildkrot
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

2.  The Effect of Acute Rises in Intraocular Pressure after Intravitreal Bevacizumab Injection on the Peripapillary Retinal Nerve Fiber Layer Thickness and the Role of Anterior Chamber Paracentesis.

Authors:  Alireza Khodabande; Mohammad Zarei; Hasan Khojasteh; Massood Mohammadi; Esmaeil Asadi Khameneh; Ali Torkashvand; Mahmood Davoodabadi
Journal:  J Curr Ophthalmol       Date:  2021-03-26

3.  Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.

Authors:  Joanne C Wen; Ester Reina-Torres; Joseph M Sherwood; Pratap Challa; Katy C Liu; Guorong Li; Jason Y H Chang; Scott W Cousins; Stefanie G Schuman; Priyatham S Mettu; W Daniel Stamer; Darryl R Overby; R Rand Allingham
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-03-01       Impact factor: 4.799

4.  Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration.

Authors:  Jeremy B Wingard; Darcie Ap Delzell; Nathan V Houlihan; Jonathan Lin; Jon P Gieser
Journal:  Clin Ophthalmol       Date:  2019-12-24

5.  Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab.

Authors:  Alper Bilgic; Laurent Kodjikian; Jay Chhablani; Anand Sudhalkar; Megha Trivedi; Viraj Vasavada; Vaishali Vasavada; Shail Vasavada; Samaresh Srivastava; Deepak Bhojwani; Aditya Sudhalkar
Journal:  J Ophthalmol       Date:  2020-01-20       Impact factor: 1.909

Review 6.  Current intravitreal therapy and ocular hypertension: A review.

Authors:  Aditya Sudhalkar; Alper Bilgic; Shail Vasavada; Laurent Kodjikian; Thibaud Mathis; Fransesc March de Ribot; Thanos Papakostas; Viraj Vasavada; Vaishali Vasavada; Samaresh Srivastava; Deepak Bhojwani; Pooja Ghia; Anand Sudhalkar
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.